Figure 1.
The CONSORT flowchart of EV71vac phase 1 clinical trial.
The detail of volunteer enrollment is now fully described in our previous report [24].
Table 1.
Summary of EV71 B4 subgenotype-specific virus neutralizing antibody titers in sera from subjects immunized with the 5 and 10 µg of EV71 vaccine as Group A and B, respectively.
Figure 2.
Virus neutralizing antibody responses of adults immunized with EV71vac against subgenotypes B1 and B5.
Panels A and B show the B1 neutralization titers of post-vaccination sera obtained with a 5- and 10-µg dose, respectively. Panels C and D show the B5 neutralization titers of post-vaccination sera obtained with a 5- and 10-µg dose, respectively. Each spot represents the neutralizing antibody response for individual serum. The bar corresponds to the geometric mean titer (GMT) of each set of sera.
Table 2.
Summary of EV71 virus neutralizing antibody titers against EV71 C2 subgenotype and CVA16 obtained from subjects immunized with the 5 and 10 µg of EV71 vaccine as Group A and B, respectively.
Figure 3.
Virus neutralizing antibody responses of adults immunized with EV71vac against subgenotypes C4A and C4B.
Panels A and B show the C4A neutralization titers of post-vaccination sera obtained with a 5- and 10-µg dose, respectively. Panels C and D display the C4B neutralization titers of post-vaccination sera obtained with a 5- and 10-µg dose, respectively. Each spot represents the neutralizing antibody response for individual sera. The bar represents the geometric mean titer (GMT) of each set of sera.
Table 3.
Summary of EV71 subgenotypes-specific virus neutralizing antibody titers obtained from naïve adult sera immunized with the 5 and 10 µg of EV71 vaccine as Group A and B, respectively.